CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to MNKD

70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)

Phase 3
MannKind Corporation (MNKD)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Diabetes Type 2

View Full Landscape
Drug Information

Target Indication

Diabetes Type 2

Clinical Trial

NCT00309244

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Insulin Aspart Injection

Treatment of diabetes mellitus

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.